TILDA MARTIN: Open Payments
NPI 1942676424 · MINDEN, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 29 payments from 8 companies in 2025. Trend: 2023 $358 · 2024 $622 · 2025 $418
Food & beverage: $418
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $163 |
| ABBVIE INC. | 4 | $100 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| PFIZER INC. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
Products named: Ozempic, VRAYLAR, Rybelsus, CAPLYTA, NURTEC ODT, UBRELVY, Veozah, TRELEGY ELLIPTA.
Industry payments across NV — which companies pay providers there.
